Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 429-434

  Zheng, Youyang ^a   Li, Yong ^b   Teng, Yaoshu ^b   Zhang, Zhen ^c   Cao, Xiaolin ^b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Head and neck carcinoma; N acetyltransferase 2; Phenotype

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MEDLINE; META ANALYSIS; MOUTH CANCER; OROPHARYNX CANCER; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84855233865     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.493     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Ferlay J, Bray F, Pisani P and Parkin D: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon, 2004.
3. Blot WJ, McLaughlin JK, Winn DM, et al: Source smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48: 3282-3287, 1988.
4. Dahlstrom KR, Adler-Storthz K, Etzel CJ, et al: Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res 9: 2620-2626, 2003.
5. Sturgis EM and Wei Q: Genetic susceptibility - molecular epidemiology of head and neck cancer. Curr Opin Oncol 14: 310-317, 2002.
6. Vineis P, Alavanja M, Buffler P, et al: Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96: 99-106, 2004.
7. Franceschi S, Talamini R, Barra S, et al: Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 50: 6502-6507, 1990.
8. Grant DM, Blum M, Beer M and Meyer UA: Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39: 184-191, 1991.
9. Blum M, Demierre A, Grant DM, Heim M and Meyer UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237-5241, 1991.
10. Smith CA, Smith G and Wolf CR: Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A: 1921-1935, 1994.
11. Hein DW: Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948: 37-66, 1998.
12. Butcher NJ, Boukouvala S, Sim E and Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2: 30-42, 2002.
13. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Bauer S, Loddenkemper R and Roots I: Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 56: 3961-3966, 1996.
14. Hein DW: N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25: 1649-1658, 2006.
15. Chen J, Stampfer MJ, Hough HL, et al: A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 58: 3307-3311, 1998.
16. Katoh T, Boissy R, Nagata N, et al: Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 85: 46-49, 2000.
17. Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A and Spencer A: Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 89: 628-629, 2004.
18. Zhang XF, Bian JC, Zhang XY, et al: Are polymorphisms of N-acetyltransferase genes susceptible to primary liver cancer in Luoyang, China? World J Gastroenterol 11: 1457-1462, 2005.
19. Chatzimichalis M, Xenellis J, Tzagaroulakis A, et al: GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. J Laryngol Otol 124: 318-323, 2010.
20. Demokan S, Suoglu Y, Gözeler M, Demir D and Dalay N: N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer. Mol Biol Rep 37: 3217-3226, 2010.
21. Buch SC, Nazar-Stewart V, Weissfeld JL and Romkes M: Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck 30: 1139-1147, 2008.
22. Harth V, Schafer M, Abel J, et al: Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 71: 887-897, 2008.
23. Boccia S, Cadoni G, Sayed-Tabatabaei FA, et al: CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol 134: 93-100, 2008.
24. Majumder M, Sikdar N, Ghosh S and Roy B: Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer 120: 2148-2156, 2007.
25. Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W and Szyfter K: The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett 224: 263-278, 2005.
26. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W and Szyfter K: CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 574: 112-123, 2005.
27. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK and Eckelt U: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 38: 486-490, 2002.
28. Varzim G, Monteiro E, Silva R, Pinheiro C and Lopes C: Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL J Otorhinolaryngol Relat Spec 64: 206-212, 2002.
29. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL and Schwartz SM: N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 22: 1993-1999, 2001.
30. Jourenkova-Mironova N, Wikman H, Bouchardy C, et al: Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 9: 533-537, 1999.
31. Henning S, Cascorbi I, Münchow B, Jahnke V and Roots I: Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics 9: 103-111, 1999.
32. Morita S, Yano M, Tsujinaka T, et al: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 80: 685-688, 1999.
33. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K and Bell DA: A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19: 1803-1807, 1998.
34. González MV, Alvarez V, Pello MF, Menéndez MJ, Suárez C and Coto E: Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 51: 294-298, 1998.
35. Hein DW, Doll MA, Fretland AJ, et al: Molecular genetics and epidemiology of the NAT1 and NAT2 acteylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42, 2000.
36. Vatsis KP, Martell Kj and Weber WW: Diverse point mutations in the human gene for polymorphic N-acetyltranferase. Proc Natl Acad Sci USA 88: 6333-6337, 1991.
37. Shen X, Zhang J, Yan Y, Yang Y, Fu G and Pu Y: Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A 72: 759-766, 2009.
38. Ladero JM, Agúndez JA, Olivera M, et al: N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. Eur J Clin Pharmacol 58: 115-118, 2002.
39. Zhang YW, Eom SY, Kim YD, et al: Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans. Int J Cancer 125: 139-145, 2009.
40. Boccia S, Sayed-Tabatabaei FA, Persiani R, et al: Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer 7: 206, 2007.
41. Chiou HL, Wu MF, Chien WP, et al: NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Lett 223: 93-101, 2005.
42. Zupa A, Sgambato A, Bianchino G, et al: GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study. Anticancer Res 29: 1709-1714, 2009.
43. Borlak J and Reamon-Buettner SM: N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 7: 58, 2006.
44. Hamasaki T, Inatomi H, Katoh T, et al: N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol 10: 167-173, 2003.
45. Hein DW, Leff MA, Ishibe N, et al: Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen 40: 161-167, 2002.
46. Iguchi T, Sugita S, Wang CY, et al: MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo 23: 7-12, 2009.
47. Gara S, Abdennebi M, Chatti S, Touati S, Ladgham A and Guemira F: Association of NAT2 gene substitution mutation T341C with increased risk for head and neck cancer in Tunisia. Acta Oncol 46: 834-837, 2007.
48. Unal M, Tamer L, Akbaş Y, et al: Genetic polymorphism of N-acetyltransferase 2 in the susceptibility to laryngeal squamous cell carcinoma. Head Neck 27: 1056-1060, 2005.
49. Lei D, Pan X, Guo C, et al: Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma. Zhonghua Zhong Liu Za Zhi 24: 154-156, 2002.